Analyst Reco. Novartis AG

Equities

Market Closed - Swiss Exchange Other stock markets 11:30:59 2024-12-10 am EST			5-day change	1st Jan Change
88.76 ^CHF	-0.69%		-4.58%	+4.58%

Dec. 10	Swiss Equities Extend Losses; KOF Global Economic Barometers Stable	MT
Dec. 10	Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment	MT

NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 10	ZD
NOVARTIS AG : Jefferies remains Neutral	Dec. 10	ZD
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation	Nov. 26	MT
NOVARTIS : Stifel raises its target price for the share	Nov. 25	CF
NOVARTIS AG : Berenberg reiterates its Neutral rating	Nov. 25	ZD
NOVARTIS AG : Gets a Neutral rating from Deutsche Bank	Nov. 22	ZD
NOVARTIS AG : Goldman Sachs sticks Neutral	Nov. 22	ZD
NOVARTIS AG : Goldman Sachs gives a Neutral rating	Nov. 21	ZD
NOVARTIS AG : Gets a Sell rating from Barclays	Nov. 21	ZD
NOVARTIS AG : JP Morgan is Neutral	Nov. 21	ZD
NOVARTIS AG : Gets a Buy rating from UBS	Nov. 21	ZD
NOVARTIS AG : Deutsche Bank sticks Neutral	Nov. 20	ZD
NOVARTIS AG : UBS reiterates its Buy rating	Nov. 14	ZD
NOVARTIS AG : JP Morgan sticks Neutral	Nov. 07	ZD
NOVARTIS AG : Goldman Sachs remains Neutral	Oct. 31	ZD
NOVARTIS AG : Bernstein reiterates its Buy rating	Oct. 30	ZD
NOVARTIS AG : Deutsche Bank reaffirms its Neutral rating	Oct. 30	ZD
NOVARTIS AG : JP Morgan gives a Neutral rating	Oct. 30	ZD
NOVARTIS AG : UBS keeps its Buy rating	Oct. 30	ZD
NOVARTIS : Q3 beat and a guidance upgrade; today’s dip is a buying opportunity	Oct. 29
NOVARTIS AG : Bernstein reiterates its Buy rating	Oct. 29	ZD
NOVARTIS AG : Goldman Sachs reaffirms its Neutral rating	Oct. 29	ZD

No results for this search

NOVARTIS : Q3 beat and a guidance upgrade; today’s dip is a buying opportunity

October 29, 2024 at 02:16 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

Novartis AG : Sandoz takes its first steps on the stock exchange